Introduction
============

Cytokinesis is the postmitotic event that physically separates the cytoplasms of the daughter cells. In both fungal and animal cells, cytokinesis is performed in two steps, cleavage-furrow formation and abscission. Formation and ingression of the cleavage furrow involve many cellular processes such as actomyosin ring (AMR) contraction, targeted membrane deposition, and ECM rearrangements ([@bib5]; [@bib6]; [@bib26]), among which the AMR is the most extensively characterized. The majority of AMR components (F-actin, type-II myosin, and other associated proteins) are conserved in fungi, amoebae, and animals ([@bib5]). Thus, the mechanisms of AMR function are likely to be conserved also in these species, although the degrees to which cleavage-furrow ingression depends on AMR contraction may vary ([@bib5]; [@bib91]). Membrane trafficking also appears to be critical for furrow ingression ([@bib62]), and perturbation of various intracellular trafficking systems has a strong impact on this process and/or on subsequent abscission ([@bib1]). The involvement of ECM rearrangements in cytokinesis is less well understood, but many types of ECM components (proteins, proteoglycans, and polysaccharides) localize to the cleavage furrow, and some of them have been shown to be required for normal cytokinesis ([@bib38]; [@bib66]; [@bib68]; [@bib101]).

After cleavage-furrow ingression, the intercellular bridge connecting the two daughter cells is disassembled to irreversibly separate the daughter cells ([@bib13]; [@bib82]; [@bib67]), a process termed abscission. In mammalian cells, abscission appears to involve anchoring of the plasma membrane to the midbody and subsequent resolution, in which the septins, secretory vesicles, and recycling endosomes are all implicated ([@bib24]; [@bib82]; [@bib67]). In *Drosophila melanogaster* S2 cells, F-actin appears to be essential for cleavage-furrow ingression but dispensable for abscission ([@bib22]), suggesting that there are AMR-dependent and -independent events in animal cytokinesis. Among the key questions for a comprehensive understanding of cytokinesis are how these events are organized temporarily and spatially to accomplish successful cytokinesis and whether there is a central regulatory molecule or system that governs them.

The budding yeast *Saccharomyces cerevisiae* is an ideal model organism for study of the AMR-independent processes involved in cytokinesis because cells lacking the only type II myosin, and hence the AMR, are viable ([@bib11]; [@bib98]). In wild-type cells, contraction of the AMR and cleavage-furrow ingression start concomitantly with synthesis of an extracellular polysaccharide, chitin, between the two layers of plasma membrane in the furrow to form the primary septum (PS; [@bib84]; [@bib98]). Chitin in the PS is synthesized mainly by the chitin synthase Chs2 ([@bib84]); the proteins Iqg1, Inn1, Hof1, and Cyk3 appear to be involved in PS formation by directly or indirectly contributing to Chs2 activation ([@bib23]; [@bib53]; [@bib47]; [@bib80]; [@bib40]; [@bib90]; [@bib69]; [@bib63]; [@bib73]). Because Chs2 is delivered to the division site by exocytosis ([@bib18]; [@bib94]), PS formation is a cytokinetic event achieved by the concerted actions of AMR contraction, membrane trafficking, and ECM rearrangement.

Because the transmembrane protein Chs2 and the AMR are both positioned at the leading edge of the cleavage furrow, where membrane fusion should take place during abscission, it is conceivable that furrow ingression and PS formation are inherently incapable of providing a mechanism for abscission because their machineries physically obstruct the process, necessitating another mechanism for abscission. An abscission defect in yeast has been observed as a consequence of perturbed spindle--midzone function ([@bib12]), and a pathway named NoCut was found ([@bib70]; [@bib65]) to be responsible for this checkpoint function, which is thought to transduce a signal from the chromatin and spindle midzone to the cortical membrane. However, the precise mechanisms of abscission in yeast remain obscure.

As PS formation nears completion, the modes of ECM rearrangement and membrane trafficking change, and the secondary septa (SSs), consisting mainly of glucan, begin to be laid down on both mother and daughter sides of the PS ([@bib14]). The completed trilamellar septum is then partially degraded by a chitinase and glucanases that are secreted asymmetrically by the daughter cell ([@bib48]; [@bib19]; [@bib14]), thereby concluding cell separation.

In animal cells, the small GTPase RhoA appears to regulate multiple processes in cytokinesis ([@bib74]; [@bib26]). RhoA is bound to the membrane by CAAX prenylation at its C terminus and activated to its GTP-bound state and concentrated at the division site by a guanine nucleotide exchange factor (GEF). RhoA-GTP then binds to various downstream effectors such as the actin-nucleator formin and the Rho-associated protein kinase to regulate AMR assembly and initiation of contraction ([@bib60]). In addition, RhoA may be involved in abscission, at least in some cell types. For example, in HeLa cells, RhoA has been reported to be activated in late telophase ([@bib104]), localize to the midbody, and promote abscission (together with Citron kinase and anillin; [@bib30]), and expression of a dominant-negative form of the RhoA GEF Ect2 caused a specific defect in abscission ([@bib16]).

During *S. cerevisiae* cytokinesis, the RhoA homologue Rho1 promotes AMR formation through the formin Bni1 ([@bib89]). Rho1 activity during this process appears to be controlled mainly by the Polo kinase Cdc5 through two GEFs, Tus1 and Rom2 ([@bib102]). Rom2 may also be regulated by phosphatidylinositol 4,5-bisphosphate (PIP~2~) produced by the Mss4 phosphatidylinositol 5-kinase in the plasma membrane ([@bib3]). PIP~2~ also contributes to the accumulation of Rho1 at the division site after mitotic exit through interaction with the polybasic sequence at the C terminus of Rho1; this pool of Rho1 can promote cytokinesis in *myo1Δ* cells via recruitment of the chitin synthase Chs3, without restoring actin ring assembly ([@bib103]). In addition, Rho1 is known to use the glucan synthases Fks1/2, the protein kinase Pkc1, and the exocyst subunit Sec3 as effectors to regulate cell wall synthesis, the cell wall integrity MAPK pathway, and exocytosis, respectively, which contribute to a broad range of cellular events such as stress response, bud growth, wound healing, and cell cycle progression ([@bib34]; [@bib51]; [@bib45], [@bib46]).

In this study, we investigated the contribution of SS formation to abscission in yeast and identified genes involved in this process by a genetic screen. Further characterization of these genes has suggested a role for Rho1 in SS formation and a novel mechanism for its regulation by the catalytically inactive transglutaminase domain in Cyk3.

Results
=======

Possible contribution of SS formation to abscission in yeast
------------------------------------------------------------

In mutants defective in anaphase-promoting complex function or degradation of Iqg1, such as *cdh1Δ*, the PS frequently fails to fully span the division plane, and the gap is filled with materials reminiscent of the SS ([@bib90]). Similar discontinuities in the PS, typically ∼40 nm in diameter, were observed also in wild-type cells ([Fig. 1 A](#fig1){ref-type="fig"}), although in lower frequency (∼5% vs. the ∼27% observed in *cdh1Δ* cells). To ask whether such discontinuities were normal structures that had been missed in conventional EM thin sections, we performed serial section EM on wild-type cells. We found such discontinuities in four of the seven cells observed ([Fig. 1 B](#fig1){ref-type="fig"}). As the discontinuities are only ∼40 nm and the sections used were ∼80 nm thick, it is likely that some were missed and that most or all wild-type septa have a similar structure. Collectively, these results, those of [@bib90], and other evidence (see Introduction) suggest that PS formation alone is not sufficient to complete cytokinesis and that abscission is delayed in mutants defective in timely disassembly of the AMR.

![**Possible contribution of SS formation to abscission in yeast.** (A and B) EM analyses showing discontinuities (brackets) in PSs (electron lucent layer) of wild-type strain YEF473A. (A) A single section. (B) Serial ∼80-nm sections of two cells. Bars, 0.5 µm. (C) Initiation of SS formation before AMR disassembly. Strain RNY1681 (*MYO1-GFP*) was cultured to exponential phase in SC medium at 24°C, stained in the growth medium with 0.05% aniline blue, and observed using standard YFP and CFP filter sets. Arrowheads show strong staining of the SS. Bar, 5 µm.](JCB_201302001_Fig1){#fig1}

Next, we asked whether the process that follows PS formation, SS formation, might contribute to abscission. We stained wild-type cells expressing Myo1-GFP with aniline blue, a dye that binds specifically to 1,3-β-glucan, the main constituent of the SS ([@bib105]). As shown in [Fig. 1 C](#fig1){ref-type="fig"}, the dye stained only general cell wall in the majority (∼90%, *n* = 104) of large-budded cells before ([Fig. 1 C](#fig1){ref-type="fig"}, image 1) and during ([Fig. 1 C](#fig1){ref-type="fig"}, image 2) AMR constriction. In contrast, in cells in which the AMR had contracted but not disassembled (*n* = 34), strong staining was usually obvious either at the periphery of the division plane (41%; [Fig. 1 C](#fig1){ref-type="fig"}, image 3) or as a continuous line across it (29%; [Fig. 1 C](#fig1){ref-type="fig"}, image 4). After AMR disassembly, cells always showed a continuous line of staining across the division plane (100%, *n* = 37; [Fig. 1 C](#fig1){ref-type="fig"}, image 5). Thus, SS formation appears to begin before the plasma membrane is resolved to separate the mother and daughter cytoplasms, suggesting that it might play a role in abscission.

Identification of Rho-related genes as dosage suppressors of PS formation mutants
---------------------------------------------------------------------------------

SS formation and its regulation remain poorly understood, mostly because of a lack of mutants or conditions that exhibit specific defects in this process. We reasoned that a dosage-suppressor screen of mutants defective in PS formation might identify genes involved in SS formation. We performed such a screen using a *cyk3Δ hof1Δ* double mutant (see Materials and methods). This mutant is almost inviable ([Fig. 2 A](#fig2){ref-type="fig"}; [@bib47]), probably as a result of its severe inefficiency in PS formation ([Fig. 3, A and E](#fig3){ref-type="fig"}). In addition to the expected *CYK3* and *HOF1*, we isolated nine suppressor genes from two independent genomic libraries ([Fig. S1 A](http://www.jcb.org/cgi/content/full/jcb.201302001/DC1){#supp1}). Six of these genes ([Fig. 2 A](#fig2){ref-type="fig"}) encode proteins functionally related to two Rho family small GTPases, Rho1 and Cdc42: *RHO1* itself and its homologue *RHO2*, proteins that function upstream and downstream of Rho1 (*MSS4* and *KDX1*, respectively), and direct regulators of Cdc42 (*RGD2* and a C-terminally truncated version of *CDC24*, designated *cdc24\**; see below). Interestingly, unlike *CYK3*, which induces Chs2-dependent PS formation ([@bib69]), most of these genes were also able to suppress *chs2Δ* ([Fig. 2 A](#fig2){ref-type="fig"}), indicating that the Rho-related genes suppress through a pathway independent of PS formation. Characterization of the other three genes, *PSP1*, *NAB6*, and *PAP1*, will be described elsewhere.

![**Suppression of *cyk3Δ hof1Δ* and *chs2Δ* growth defects by activation of Rho1 or inactivation of Cdc42.** (A) *cyk3Δ hof1Δ* (MOY68) and *chs2Δ* (RNY1419) strains carrying a *URA3 HOF1* or *URA3 CHS2* plasmid were transformed with *LEU2*-marked high-copy plasmids containing the indicated genes ([Table 2](#tbl2){ref-type="table"}). The transformants were cultured overnight in SC-Ura-Leu medium, spotted onto SC-Leu + 5-FOA plates as serial 5× dilutions starting at ∼10^6^ cells per spot, and imaged after 4 d at 24°C. Spotting of equal numbers of cells was confirmed by spotting onto SC-Ura-Leu plates (not depicted). These data are shown again in [Fig. S1 A](http://www.jcb.org/cgi/content/full/jcb.201302001/DC1){#supp2} alongside additional strains. (B) Suppression of *cyk3Δ hof1Δ* by deletion of *SAC7*, *LRG1*, or *PXL1*. Strains of the indicated genotypes (MOY68, MOY438, MOY433, and MOY430) were streaked on a SC + 5-FOA plate to eliminate their *URA3 HOF1* plasmids and incubated at 24°C for 4 d. Streaking was used here because the relatively weak suppression was masked in spotting assays by the presence of a few large colonies that presumably represented spontaneous suppressors. (C) Summary of activating and inhibitory interactions inferred from the suppression results. Cdc24\* and Pxl1 are discussed in the legends of [Fig. S3](http://www.jcb.org/cgi/content/full/jcb.201302001/DC1){#supp3} and [Fig. S4](http://www.jcb.org/cgi/content/full/jcb.201302001/DC1){#supp4}. Question marks show interactions postulated to exist because *RHO1* and *RHO2* suppress more strongly than does *KDX1* and because *cdc24\** and *RGD2* suppress more strongly than does *pxl1Δ*.](JCB_201302001_Fig2){#fig2}

![**Thickened SS without restoration of PS when Rho-related genes are expressed in *cyk3Δ hof1Δ* cells.** (A--D) *cyk3Δ hof1Δ* strains overexpressing the indicated genes ([Fig. 2 A](#fig2){ref-type="fig"}) were streaked on SC + 5-FOA plates to eliminate the *URA3*-marked *HOF1* plasmid and observed by EM. (A) RNY2127, (B) MOY245, (C) MOY682, and (D) MOY78. Bars, 0.5 µm. (E) For each strain, cells with any visible septal structure were scored for successful bud-neck closure (left) and the presence of PS-like structures (right). Data for *RHO2* are from the experiment in [Fig. S3 A](http://www.jcb.org/cgi/content/full/jcb.201302001/DC1){#supp5} Black bars show control strains without plasmid. Gray bars show mutant strains transformed with plasmids overexpressing the indicated genes.](JCB_201302001_Fig3){#fig3}

Consistent with the independence of suppression from Chs2, little or no improvement in PS formation was observed during suppression by *RHO1* or *RHO2* ([Fig. 3, B and E](#fig3){ref-type="fig"}, right; and [Fig. S2 A](http://www.jcb.org/cgi/content/full/jcb.201302001/DC1){#supp6}), *RGD2* ([Fig. 3, C and E](#fig3){ref-type="fig"}), *cdc24\** ([Fig. 3, D and E](#fig3){ref-type="fig"}), or *KDX1* (not depicted). Instead, the suppressed cells had very thick SS-like structures that spanned the bud necks with slightly better efficiency than was seen in control cells ([Fig. 3 E](#fig3){ref-type="fig"}, left), probably accounting for the higher growth rates of the suppressed cells. These results suggest that the Rho-related genes hyperactivate SS formation and that the SS can be an alternative to the PS as a driving force for successful (albeit abnormal) cytokinesis. Similar improvements in growth and hyperactivation of SS formation were observed using an *iqg1Δ* mutant (Fig. S1 A and Fig. S2, B--E), indicating that the suppression mechanisms do not require the AMR, which fails to form in *iqg1Δ* mutants ([@bib23]; [@bib53]). Interestingly, many *cyk3Δ hof1Δ* cells suppressed by *RHO1* or *RHO2* had SS without detectable PS ([Fig. 3, B and E](#fig3){ref-type="fig"}; and Fig. S2 A), suggesting that these genes (but not *cdc24\** or *RGD2*) also have inhibitory effects on PS formation.

Hyperactivation of SS formation by activation of Rho1 or inactivation of Cdc42
------------------------------------------------------------------------------

Each of the aforementioned suppressors either activates the Rho1 pathway or inactivates the Cdc42 pathway, with the apparent exception of *cdc24\**. We extended the test to other GEFs and GTPase-activating proteins (GAPs) that regulate these small GTPases. Activation of Rho1 by either overexpression of certain Rho1-GEF genes (*TUS1* and *ROM1*) or deletion of certain Rho1-GAP genes (*SAC7* or *LRG1*) suppressed *cyk3Δ hof1Δ* (Fig. S1 B and [Fig. 2 B](#fig2){ref-type="fig"}, left and middle images). In striking contrast to *cdc24\**, wild-type *CDC24* failed to suppress *cyk3Δ hof1Δ* (Fig. S1 B). Further analyses ([Fig. S3](http://www.jcb.org/cgi/content/full/jcb.201302001/DC1){#supp7}) suggested that the chimeric Cdc24\* protein, consisting of portions of Cdc24 and of the *tetA* tetracycline resistance protein (from the vector backbone), functions as an inhibitor of Cdc42. Consistent with this hypothesis, overexpression of certain Cdc42 GAPs (*RGA1* and *BEM3*) also suppressed the *cyk3Δ hof1Δ* mutant (Fig. S1 B). Interestingly, *RGD1*, which encodes a GAP for Rho3 and Rho4 ([@bib76]), also suppressed the mutant, suggesting that these proteins may also be involved in cytokinesis. In most cases, suppression of an *iqg1Δ* mutant paralleled those with the *cyk3Δ hof1Δ* mutant (Fig. S1, A and B). Collectively, our genetic data support the model that either activation of Rho1 or inactivation of Cdc42 is sufficient to suppress effects in AMR and/or PS formation by inducing SS formation ([Fig. 2 C](#fig2){ref-type="fig"}).

We also found that deletion of the paxillin homologue gene *PXL1* weakly suppressed both *cyk3Δ hof1Δ* and *hof1Δ* ([Fig. 2 B](#fig2){ref-type="fig"} and [Fig. S4 A](http://www.jcb.org/cgi/content/full/jcb.201302001/DC1){#supp8}). *PXL1* was identified as an allele-specific dosage suppressor of *cdc42* point mutations, and both genetic and biochemical evidence suggests that Pxl1 is a negative regulator of Rho1 ([@bib31]; [@bib57]). Because the timing and pattern of Pxl1-GFP localization also coincide with that of SS formation (Fig. S4, B--D), it seems likely that Pxl1 connects Cdc42 and Rho1 during SS formation ([Fig. 2 C](#fig2){ref-type="fig"}), serving as a molecular brake for excessive SS formation.

Requirement for Rho1 in SS formation and cell separation
--------------------------------------------------------

The extensive formation of SS when Rho1 was overexpressed or activated in cytokinesis mutants suggested that it may have a role in SS formation in wild-type cells. To test this hypothesis, we induced the expression of a GDP-locked, dominant-negative mutant of Rho1 (T24N) in cells released from an anaphase block produced by a *cdc15-2* mutation. Under these conditions, the AMR was already formed at the time of release (not depicted; [@bib102]), and the initiation and rate of furrow ingression were not affected by the expression of Rho1^T24N^ ([Fig. 4, A and D](#fig4){ref-type="fig"}). However, the Rho1^T24N^-expressing cells completely failed to separate even after 105 min ([Fig. 4 A](#fig4){ref-type="fig"}) or 12 h (not depicted). Some cells eventually formed tiny buds ([Fig. 4, A and C](#fig4){ref-type="fig"}), indicating that the cells did not simply die upon induction of Rho1^T24N^ and thus that the separation defect was triggered specifically by inhibition of a Rho1 pathway. EM analyses revealed that at 75 min, ∼87% of control cells had formed SS ([Fig. 4 F](#fig4){ref-type="fig"}, top), whereas only ∼30% of the Rho1^T24N^-expressing cells had detectable SS even though normal-looking PSs were formed ([Fig. 4 F](#fig4){ref-type="fig"}, bottom), indicating that SS formation was blocked or delayed by the dominant-negative Rho1.

![**Dependence of SS formation and cell separation, but not cleavage-furrow ingression, on Rho1 activity.** (A--D) Effects of dominant-negative Rho1. A *cdc15-2 MYO1-GFP* (YCp-P~GAL~-RHO1^T24N^) strain (MOY542) was synchronized by incubation at 37°C in SC-Leu (2% raffinose) medium (A, C, and D, right) or with nocodazole in YPD (2% raffinose) medium (B; see Materials and methods). Each culture was separated into two and released from the block in the presence (+GAL) or absence (−GAL) of 2% galactose. (A and B) At the indicated times, aliquots of cells were fixed with formaldehyde, sonicated briefly, and scored for the percentages of cells with large (precontraction) Myo1-GFP rings, large buds, large buds plus one or more new buds, no buds, and small or medium buds (*n* \> 200 per sample). Plasmid loss during incubation in the nonselective medium presumably accounts for the reduced efficiency of cell separation blockage in B. (C) Representative cells at 105 min in the +GAL culture of A. Arrowheads show new buds formed before cell separation. (D) Asynchronous cells in SC-Leu (2% raffinose) medium and *cdc15-2*--synchronized cells were observed by time-lapse microscopy beginning 15 min after addition (or not) of galactose. The time intervals between initiation of Myo1-GFP contraction and Myo1-GFP disappearance were recorded as constriction times. The long and short horizontal bars indicate means and means ± SDs, respectively. Student's unpaired *t* tests showed that the differences in mean values were not significant. Data from three separate experiments were combined; *n* = 10, 12, 13, and 12 (left to right). (E) Cell morphologies of Rho1 GEF mutants. Strains of the indicated genotypes (YEF473A, RNY879, RNY935, and RNY875) were cultured in YM-P medium to exponential phase. Arrowheads show new buds formed before cell separation. The percentages of such cells among total large-budded cells are indicated (*n* = 300). (F) Effect of Rho1^T24N^ on septum morphology. Control (−GAL) and Rho1^T24N^-expressing (+GAL) cells from the 75-min sample in A were observed by EM. Counts of septa with PS only or with both PS and SS are shown on the right. Bars: (C and E) 5 µm; (F) 0.2 µm.](JCB_201302001_Fig4){#fig4}

Importantly, although Rho1 activity in early stages of cytokinesis is required for AMR formation (and possibly also for its contractility), it appeared to be dispensable for cleavage-furrow ingression, as indicated by nearly normal constriction of Myo1-GFP rings in Rho1^T24N^-expressing cells that had been synchronized with nocodazole at a stage before actin ring formation ([Fig. 4 B](#fig4){ref-type="fig"} and not depicted) as well as in asynchronous culture ([Fig. 4 D](#fig4){ref-type="fig"} and not depicted). These results are consistent with the dispensability of the AMR and its contractility for cleavage-furrow formation in yeast (see Introduction).

Examination of Rho1-GEF mutants revealed that *tus1Δ* cells also exhibited bud emergence before cell separation, whereas *rom1Δ* and *rom2Δ* cells did not ([Fig. 4 E](#fig4){ref-type="fig"}). Interestingly, of 30 *tus1Δ* cells examined by EM, 40% had apparently complete PSs without SS, and 50% had SS only on the daughter side of the PS ([Fig. S5 A](http://www.jcb.org/cgi/content/full/jcb.201302001/DC1){#supp9} and not depicted). As Tus1 remains at the bud neck after the furrow and AMR have constricted ([@bib102]), and overexpression of *TUS1* (but not of *ROM1* or *ROM2*) could suppress *cyk3Δ hof1Δ*, *iqg1Δ*, and *chs2Δ* mutations (Fig. S1 B), this GEF may be primarily responsible for Rho1 activation during SS formation. Conversely, hyperactivation of Rho1 either by expression of a constitutively active construct (Rho1^Q68L^) or by deletion of the GAP gene *LRG1* caused formation of abnormally thickened SS (Fig. S5 A). Surprisingly, deletion of another GAP gene, *SAC7*, did not have a strong impact on SS structure (Fig. S5 A), although this deletion was at least as effective as *lrg1Δ* in suppressing *cyk3Δ hof1Δ* ([Fig. 2 B](#fig2){ref-type="fig"}). Collectively, these results suggest that Rho1 has a role in SS formation as well as in actin ring formation during normal cytokinesis and that Tus1 and Lrg1 are its major positive and negative regulators for this role.

Temporary inactivation of Rho1 during AMR constriction and PS formation
-----------------------------------------------------------------------

Both Rho1 ([@bib103]) and its effector Fks1 (glucan synthase; [Fig. 5](#fig5){ref-type="fig"}) arrive at the division site before cleavage-furrow ingression and hence before the initiation of SS formation. These observations suggest that Rho1 activity might be specifically suppressed during PS formation to prevent premature activation of SS formation. Consistent with this hypothesis, expression of the constitutively active Rho1^Q68L^ caused a substantial increase in the number of cell clusters (Fig. S5 B), suggesting that Rho1^Q68L^ interferes with a step in cell division. To explore the hypothesis further, we conducted pull-down assays using *cdc15-2--*synchronized cells and a GST-fused Rho-binding domain (RBD) from Pkc1, which binds specifically to GTP-bound Rho1 ([@bib45]). As reported previously ([@bib102]), Rho1 activity was high in the arrested cells ([Fig. 6, A and B](#fig6){ref-type="fig"}, 0 min). It then decreased during the 30 min after release and generally remained low until 75 min, except for a small increase at 45 min that was observed in each of three independent experiments ([Fig. 6, A and B](#fig6){ref-type="fig"}). In parallel experiments, furrow ingression started at \<40 min after release ([Fig. 6 C](#fig6){ref-type="fig"}) and was typically complete within 7--10 min in each cell (not depicted). Because SS formation begins before AMR disassembly ([Fig. 1 C](#fig1){ref-type="fig"}), the transient activation of Rho1 coincides with, and is probably responsible for, the initiation of SS formation. The later activation of Rho1 beginning at ∼75--90 min is presumably associated with bud growth in the new cell cycle ([@bib45]).

![**Localization of Fks1 to the division site during AMR constriction and before the beginning of SS formation.** Strain MOY1303 (*FKS1-GFP fks2Δ MYO1-CFP*) was observed by time-lapse microscopy in YM-P medium. Whole-cell images of one cell (top) and kymographs of the division planes of two other cells (bottom) are shown. Heights of the kymographs correspond to 2 µm. Numbers at the top are time in minutes after the beginning of observation. DIC, difference interference contrast. Bar, 5 µm.](JCB_201302001_Fig5){#fig5}

![**Temporary inactivation of Rho1 during PS formation and its apparent regulation by Cyk3.** (A and B) Activity of Rho1 during cytokinesis in wild-type, *cyk3Δ*, and *cyk3^TGcΔ^* cells. *cdc15-2 3HA-RHO1* (MOY553), *cdc15-2 3HA-RHO1 cyk3Δ* (MOY552), and *cdc15-2 3HA-RHO1 cyk3^TGcΔ^* (MOY973) strains were grown to exponential phase in YM-P medium at 24°C, arrested by incubation at 37°C for 3 h, and then released into mitotic exit by cooling rapidly (∼5 min) to 24°C. Samples were collected at the indicated times (minutes) and subjected to the GST-RBD pull-down assay (see Materials and methods). Numbers of independent experiments: WT, 3; *cyk3Δ*, 2; and *cyk3^TGcΔ^*, 2. (A) Representative Western blots of active and total Rho1. Asterisks show the position of a 25.9-kD molecular mass marker. (B) Quantification of band intensities (means ± SDs) of active Rho1 relative to total Rho1; the values at time 0 were set to 1.0. (C) Normal initiation of Myo1-GFP constriction in *cyk3Δ* cells and timing of Cyk3 localization to the bud neck. *cdc15-2 MYO1-GFP* (MOY720), *cdc15-2 MYO1-GFP cyk3Δ* (MOY721), and *cdc15-2 CYK3-GFP* (MOY543) strains were synchronized as in A. For Myo1-GFP, large-budded cells were scored for the presence of large (i.e., precontraction) or smaller GFP rings (*n* = 64--111 per sample). For Cyk3-GFP, large-budded cells were scored for the presence of detectable GFP signal at the neck (*n* = 124). (D) Genetic interaction between *CYK3* and *SAC7*. Strains of the indicated genotypes were spotted on YPD plates as in [Fig. 2 A](#fig2){ref-type="fig"} and incubated at 24°C for 48 h (strains: YEF473B, MOY585, MOY882, MWY636, MWY1412, MOY405, MOY440, MOY967, MOY980, and MOY982). WT, wild type.](JCB_201302001_Fig6){#fig6}

Possible regulation of Rho1 inactivation through physical interaction with Cyk3
-------------------------------------------------------------------------------

Several observations suggest that Cyk3 might be involved in a Rho1 inactivation mechanism that functions during PS formation. First, in *cdc15-2*--synchronized cells, Cyk3-GFP localized to the bud neck just before furrow ingression ([Fig. 6 C](#fig6){ref-type="fig"}), which coincides with the timing of Rho1 inactivation. Second, in contrast to wild-type cells, *cyk3Δ* cells formed PS and SS simultaneously ([Fig. 7 A](#fig7){ref-type="fig"}, left and center), suggesting that the putative temporary suppression of SS formation by Rho1 inactivation does not function properly in this mutant. Third, overexpression of Cyk3 abolished the simultaneous formation of PS and SS observed in a mitotic exit network mutant that was forced to exit mitosis with the cyclin inhibitor Sic1 ([@bib63]). Fourth, the severe clustering phenotype of *cyk3Δ* cells ([Fig. 7 B](#fig7){ref-type="fig"}, left and center) appears to involve activation of Rho1 because deletion of *CYK3* did not exacerbate the similar phenotype produced by the constitutively active Rho1^Q68L^ (Fig. S5 B). Fifth, *cyk3Δ* showed a synergistic growth defect at 24°C with the Rho1-GAP mutation *sac7Δ* ([Fig. 6 D](#fig6){ref-type="fig"}) but not with another Rho1-GAP mutation, *lrg1Δ* (not depicted). Lrg1, like Cyk3, localizes to the neck (as well as to the bud tip; [@bib95]), whereas Sac7 localizes throughout the cell cortex ([Fig. 8 D, image 5](#fig8){ref-type="fig"}), and a *sac7Δ lrg1Δ* mutant is inviable ([@bib55]). Thus, collectively, the data suggest that Cyk3, like Lrg1 ([@bib88]), is involved in controlling Rho1 activity at the neck, whereas Sac7 has a more general role, and that the excessive activation of Rho 1 when both systems are inactive is harmful or even lethal. Finally, the temporary inactivation of Rho1 completely disappeared in *cyk3Δ* cells ([Fig. 6, A and B](#fig6){ref-type="fig"}), although Myo1-GFP constriction initiated normally ([Fig. 6 C](#fig6){ref-type="fig"}).

![**Septum morphology and cell separation in *cyk3* mutants.** (A) Simultaneous formation of PS and SS in *cyk3Δ* and *cyk3^TGcΔ^* mutants. Wild-type (YEF473A), *cyk3Δ* (RNY502), and *cyk3^TGcΔ^* (MOY882) cells were observed by EM. Arrows show PS; arrowheads show SS. Bar, 0.5 µm. (B) The *cdc15-2*--synchronized cells from the experiment of [Fig. 6 A](#fig6){ref-type="fig"} were scored for bud morphology. *n* \> 200 for each time point. Numbers at the bottom indicate times (in minutes) after release from the *cdc15-2* block. WT, wild type.](JCB_201302001_Fig7){#fig7}

![**Physical interaction between Cyk3 and Rho1.** (A) Domain structure of Cyk3. SH3, src-homology domain; PLPPLPPLP, proline-rich motif; TGc, transglutaminase core domain. The previously known interactions with Inn1 and Hof1 and the interaction with Rho1 identified in this study are indicated. (B) Cells expressing 3HA-tagged Rho1 (MOY522) were grown to exponential phase in YM-P medium at 24°C, and pull-down was performed (top) using bacterially expressed GST, GST-Cyk3, or GST-Cyk3^480--885^ (see Materials and methods). Hof1-TAP (strain MOY22) was included here as a control (middle) because Hof1 is known to bind to the PLPPLPPLP motif of Cyk3 (unpublished data). (bottom) The GST proteins used were also analyzed by SDS-PAGE; the arrowheads indicate the full-length proteins. (top) Note that there appears to have been relatively little full-length GST-Cyk3 (because of proteolysis or premature translation termination), yet pull-down by this preparation was quite effective. This may mean that binding of Cyk3 to Rho1 normally involves a site in the N-terminal region as well as that in the C-terminal region. The migration positions of molecular mass markers are indicated. (C) Selective affinity of the Cyk3 C terminus for Rho1-GDP. 3HA-tagged wild-type (WT; strain MOY801), dominant-negative (T24N; strain MOY824), and constitutively active (Q68L; strain MOY803) Rho1 proteins were expressed under the control of the *GAL1* promoter for 30 min at 24°C. Cell extracts were analyzed as in B using GST-Cyk3^480--885^ or (as a control) the GST-tagged RBD ([Fig. 6](#fig6){ref-type="fig"}). (D--F) BiFC revealing interactions between Rho1 and other proteins. Strains expressing the indicated proteins (MOY1247, MOY1269, MOY1293, MOY1294, MOY1275, MOY1321, MOY1349, MOY1325, and MOY1384) were grown to exponential phase in SC-Leu liquid medium at 24°C and observed by fluorescence microscopy. (D and E) Numbering is for ease of reference in the text. Cell outlines are shown in 1 and 6 where there is no fluorescence signal. (F) The percentage of large-budded cells with detectable BiFC signal at the bud neck is shown for each strain. Bars, 5 µm.](JCB_201302001_Fig8){#fig8}

Several lines of evidence indicate that Cyk3 might inactivate or block activation of Rho1 by physically interacting with its inactive form. First, a pull-down assay using bacterially expressed, GST-fused full-length Cyk3 (GST-Cyk3) or its C-terminal half (GST-Cyk3^480--885^; [Fig. 8 A](#fig8){ref-type="fig"}) revealed that Rho1 interacted with the C-terminal half of Cyk3 ([Fig. 8 B](#fig8){ref-type="fig"}), in contrast to Hof1, which bound only to full-length GST-Cyk3 in this assay ([Fig. 8 B](#fig8){ref-type="fig"}). Second, a similar experiment using wild-type, constitutively active (Q68L), or dominant-negative (T24N) Rho1 revealed that the affinity of Rho1 for the C-terminal half of Cyk3 was significantly increased by the T24N mutation but not by the Q68L mutation ([Fig. 8 C](#fig8){ref-type="fig"}). Third, although we have not detected a Cyk3--Rho1 interaction in vivo by coimmunoprecipitation (presumably because of the membrane association of both proteins and/or the transient nature of the interaction), we have detected an interaction using bimolecular fluorescence complementation (BiFC). We constructed a Rho1 BiFC reporter by fusing the C-terminal portion (aa 155--238) of the Venus protein to the N terminus of Rho1 via a short linker (VC155-GGSGGS-Rho1; henceforth simply VC-Rho1) and expressed this construct from a low-copy plasmid in *rho1Δ* cells. This reporter successfully detected interactions of Rho1 with several GEFs and GAPs ([Fig. 8 D](#fig8){ref-type="fig"}, images 1--5). We then tagged the C terminus of Cyk3 with the N-terminal portion of Venus (aa 1--155) containing an amino acid substitution (I153L) to diminish potential self-assembly between the N- and C-terminal portions of Venus ([@bib44]). A *CYK3-VN* strain showed no detectable fluorescence ([Fig. 8 D](#fig8){ref-type="fig"}, image 6), but when VC-Rho1 was also expressed, clear BiFC signal appeared at the bud neck in a temporarily regulated manner ([Fig. 8 E](#fig8){ref-type="fig"}). In most cells with large Myo1-CFP rings, signal was not detected ([Fig. 8 E](#fig8){ref-type="fig"}, cells 1 and 2), but it did appear in some such cells (cells 3 and 4), and it remained while Myo1-CFP constricted to a dot ([Fig. 8 E](#fig8){ref-type="fig"}, cells 5 and 6). After AMR disassembly, BiFC signal remained at the bud neck ([Fig. 8 E](#fig8){ref-type="fig"}, cell 7), but this signal persistence may reflect only the tight binding between the N- and C-terminal Venus fragments ([@bib44]) rather than a continuing association of Cyk3 with Rho1 during SS formation.

The N-terminal portion of Cyk3 contains an SH3 domain and a proline-rich region, which bind to Inn1 and Hof1, which are involved in PS formation ([Fig. 8 A](#fig8){ref-type="fig"}; our unpublished data; [@bib69]; [@bib40]; [@bib64]; [@bib49]). The C-terminal portion of Cyk3 contains a transglutaminase core (TGc) domain that resembles the protein and peptide cross-linking transglutaminases. Interestingly, several transglutaminases are implicated in the modification and activation of mammalian RhoA (see Discussion). However, the TGc domain in Cyk3 lacks the conserved cysteine that is essential for TGase activity ([@bib58]; [@bib75]). We constructed a strain in which the TGc domain (aa 519--580) is deleted (*cyk3^TGcΔ^*). Cyk3^TGcΔ^ appears to retain most Cyk3 functionality because a *cyk3^TGcΔ^ hof1Δ* double mutant (in contrast to a *cyk3Δ hof1Δ* double mutant: [Fig. 2 A](#fig2){ref-type="fig"}) grew as well as a *hof1Δ* single mutant, Myo1-GFP constricted at a normal rate in *cyk3^TGcΔ^* cells, and Cyk3^TGcΔ^-GFP localized normally to the bud neck (not depicted). However, *cyk3^TGcΔ^ sac7Δ* cells grew as poorly as *cyk3Δ sac7Δ* cells ([Fig. 6 D](#fig6){ref-type="fig"}). In contrast, mutations in the SH3 domain (*cyk3^W45A^*) or the proline-rich region (*cyk3^P188,191A^*) did not cause such a synergistic growth defect with *sac7Δ* ([Fig. 6 D](#fig6){ref-type="fig"}). The *cyk3^TGcΔ^* strain showed a partial deficiency in Rho1 inactivation as judged by the GST-RBD pull-down assay ([Fig. 6, A and B](#fig6){ref-type="fig"}), a moderate premature formation of SS formation ([Fig. 7 A](#fig7){ref-type="fig"}, right), and a moderate delay in cell separation ([Fig. 7 B](#fig7){ref-type="fig"}, right). Finally, no Cyk3--Rho1 interaction could be detected by the BiFC assay when the TGc domain was deleted ([Fig. 8 F](#fig8){ref-type="fig"}). Collectively, these results suggest that the TGc domain of Cyk3 is required for effective blockage of Rho1 activation, that this role of Cyk3 is independent of its binding to the PS formation proteins Inn1 and Hof1, and that the more severe phenotype of *cyk3Δ* cells (compared with *cyk3^W45A^*, *cyk3^P188,191A^*, and *cyk3^TGcΔ^* cells) may be a synthetic effect of slowed PS formation together with a premature activation of SS formation.

Discussion
==========

SS formation as the mechanism of yeast abscission
-------------------------------------------------

In animal cells, it has long been recognized that abscission, the final resolution of the daughter cell membranes, is a step distinct from cleavage-furrow ingression ([@bib82]; [@bib67]). However, in yeast, this idea has been controversial, in part because conventional EM images have typically shown a PS that appears to span the entire division plane ([@bib97]; [@bib98]). Nonetheless, studies using mutants and fluorescent membrane markers have suggested that a distinct abscission step exists and is specifically inhibited in response to spindle midzone and chromosome segregation defects by the NoCut checkpoint pathway ([@bib70]; [@bib65]). Some septin mutants also appear to be specifically defective in abscission ([@bib21]; [@bib99]). Our serial section EM revealed a discontinuity in the PSs of most wild-type cells, supporting the hypothesis that a distinct abscission step is needed to complete cytokinesis. We suggest that the abscission machinery must be distinct from the AMR and PS formation machinery because these elements localize to the leading edge of the cleavage furrow, where they would presumably interfere with the membrane fusion needed for abscission. In support of this idea, the PS discontinuity is enlarged in mutants defective in timely disassembly of the AMR ([@bib90]).

Several lines of evidence suggest that SS formation is involved in abscission. First, 1,3-β-glucan, the major constituent of the SS, began to be deposited at the bud neck before the AMR was disassembled (and thus before abscission). Second, the glucan synthase Fks1 localized on the surface of the cleavage furrow, but in the area trailing the AMR, and so is positioned to function without physically interfering with membrane resolution. Finally, hyperactivation of SS formation restored abscission in mutants defective in PS formation. Mechanisms other than glucan synthesis are probably also involved in SS formation and abscission. In particular, the chitin synthase Chs3 is required for formation of remedial SS in a *chs2* mutant ([@bib84]), as well as in *myo1Δ* cells overexpressing Rho1 ([@bib103]), and so is likely to be involved in normal SS formation as well.

Antagonistic regulation of SS formation by Rho1 and Cdc42
---------------------------------------------------------

Our suppression data suggest that the small GTPases Rho1 and Cdc42 act antagonistically to regulate SS formation ([Fig. 2 C](#fig2){ref-type="fig"} and [Fig. 9 C](#fig9){ref-type="fig"}). Rho1 appears to promote SS formation, in that its overexpression or activation hyperactivated SS formation. Promotion of SS formation by Rho1 has also been observed in a *myo1Δ* mutant ([@bib103]), and it has been hypothesized that Rho1 is involved in SS formation in wild-type cells ([@bib97]; [@bib98]). We have provided strong support for this hypothesis by showing that expression of a dominant-negative Rho1 in synchronized cells blocks cell division but not cleavage-furrow ingression. During SS formation, Rho1 effectors implicated in cell wall synthesis and stress response are likely to be activated, such as the glucan synthases Fks1 and Fks2 ([@bib61]; [@bib77]), the protein kinase Pkc1 (through activation of the MAPK pathway, in which Kdx1 \[also known as Mlp1\] is involved; [@bib96]; [@bib42]), and Chs3 ([@bib92]; [@bib103]). In support of this hypothesis, deletions of these genes exhibit synthetic growth defects with *myo1Δ* (our unpublished data; [@bib78]; [@bib103]).

![**Model for regulation of Rho1 activity through cytokinesis.** (A) In anaphase, Rho1 is recruited to the division site and activated by GEFs, and it promotes actin polymerization through the formin Bni1 to form the AMR ([@bib89]). The Polo kinase Cdc5 activates the GEFs by phosphorylation ([@bib102]). (B) During PS formation and cleavage-furrow ingression, Cyk3 binds to Rho1 to inhibit its activation (this study), perhaps by competing with the GEFs. Abnormally activated Rho1 at this stage can inhibit PS formation. Localization of Rho1 to the cleavage furrow is mediated through its binding to PIP~2~ ([@bib103]). Cyk3 also interacts with Inn1 and Hof1 to activate PS formation under the control of Iqg1 and the mitotic exit network (see Introduction). (C) During SS formation and abscission, Rho1 (and apparently also Rho2) promotes SS formation through the MAPK pathway, Fks1 activation, and potentially other effectors (this study). Activation of Rho1 is due mostly to the GEF Tus1 and potentially also through binding to PIP~2~ ([@bib103]; this study). Rho1 also appears to be negatively regulated by Cdc42 (through Pxl1 and perhaps also directly), perhaps to avoid hyperactivation. Cdc42 may also inhibit SS formation through Ste20 (unpublished data; [@bib2]). MEN, mitotic exit network. Question marks show interaction inferred but not demonstrated directly ([Fig. 2](#fig2){ref-type="fig"}).](JCB_201302001_Fig9){#fig9}

In contrast, Cdc42 appears to inhibit SS formation ([Fig. 2 C](#fig2){ref-type="fig"} and [Fig. 9 C](#fig9){ref-type="fig"}), as its inactivation by overexpression of certain GAPs or the abnormal Cdc24\* suppressed mutants defective in PS formation. The available evidence suggests that Cdc42 functions both by inactivation of Rho1 and by an independent mechanism. Deletion of *PXL1*, a factor downstream of Cdc42 that inactivates Rho1 ([@bib31]; [@bib57]), suppressed *cyk3Δ hof1Δ*, but it did so more weakly than overexpression of either the Cdc42-GAP *Rgd2* or Cdc24\*. In addition, unlike Rho1, Cdc42 GAPs did not inhibit PS formation while activating SS formation. Although the exact mechanisms remain to be determined, Atkins et al. (in this issue) have shown that the p21-activated kinase Ste20 functions downstream of Cdc42 in cytokinesis, and we have independently confirmed that *ste20Δ* bypasses the defects in *cyk3Δ hof1Δ* by hyperactivation of SS formation (unpublished data). The relevant substrate of Ste20 remains to be identified.

The most downstream known components of the NoCut checkpoint pathway are the homologous Boi1 and Boi2 proteins in the cell cortex ([@bib65]), which interact both genetically and physically with Cdc42, Rho3, Rho4, and the scaffold protein Bem1 ([@bib9]; [@bib59]). Thus, it will be interesting to test whether the NoCut pathway acts through these GTPases. Similarly, the ER surveillance pathway delays cytokinesis upon ER stress, and the Pkc1-MAPK cascade downstream of Rho1 becomes essential for cell survival ([@bib4]). An attractive model would be that the ER surveillance pathway delays cytokinesis at abscission, giving the cell time to adjust to the stress, and then hyperactivates SS formation through Rho1 activation to resume cell division.

Dispensability and temporary inactivation of Rho1 during cleavage-furrow ingression
-----------------------------------------------------------------------------------

As Rho1 is required for AMR formation in anaphase ([Fig. 9 A](#fig9){ref-type="fig"}; [@bib102]), our results suggest that Rho1 activity is required at both the beginning and the end of cytokinesis. Because Rho1 localizes to the division site throughout cytokinesis ([@bib103]; our unpublished data), it seemed likely that Rho1 simply remained active during the entire process. However, we found that in *cdc15-2*--synchronized cells, in which AMR formation and cleavage-furrow ingression are temporarily separated, global Rho1 activity decreased substantially before furrow ingression, suggesting that the activity Rho1 might decrease even more dramatically at the division site. Moreover, Rho1^T24N^ did not block AMR constriction or PS formation, suggesting that Rho1 activity is dispensable for these processes. Indeed, overexpression of Rho1 significantly inhibited PS formation in cells (*cyk3Δ hof1Δ*) in which this process is already inefficient, suggesting that active Rho1 may actually inhibit PS formation. The dispensability of Rho1 for PS formation seems surprising given that proper localization of Chs2 requires the exocyst subunit Sec3 ([@bib94]), which is regulated by Rho1 as an effector ([@bib34]). However, another Rho protein, such as Rho3 or Cdc42 ([@bib100]), may be primarily responsible for Chs2 delivery during PS formation.

It remains possible that a small quantity of active Rho1 localizes to the leading edge of the cleavage furrow and promotes AMR contractility as seen in many other organisms ([Fig. 9 B](#fig9){ref-type="fig"}; [@bib5]; [@bib74]; [@bib8]). However, because of the force provided by PS formation, the AMR in *S. cerevisiae* can constrict at a nearly normal rate even when no force is provided by actomyosin contractility ([@bib56]; [@bib25]), making it difficult to assess intrinsic AMR contractility in this system.

Consistent with our observations in yeast, it appears that in at least some types of mammalian cells, a deficiency in RhoA activity at the division site does not block furrow ingression ([@bib71]; [@bib104]). Thus, once the AMR is formed and its contraction is initiated, RhoA may not be required for further cleavage-furrow ingression, and its role in abscission ([@bib16]; [@bib30]) may be more important.

Temporary inactivation of Rho1 by Cyk3 during cleavage-furrow ingression
------------------------------------------------------------------------

Cyk3 was originally identified as a dosage suppressor of *iqg1Δ* ([@bib47]), and its overexpression has been found to promote PS formation in both wild-type and mutant (*hof1Δ*, *myo1Δ*, *inn1Δ*, and a hypomorphic *chs2* mutation) strains (our unpublished data; [@bib69]; [@bib72]; [@bib98]). Subsequent studies have shown that binding of the SH3 domain and PXXP motifs of Cyk3 to Inn1 and Hof1, respectively, is important for PS formation (unpublished data; [@bib69]; [@bib64]). In addition, it has been reported that overexpression of Cyk3 suppressed SS formation in a mitotic exit network mutant forced to exit from mitosis ([@bib63]), although the mechanism was not defined. In this study, we found a previously unknown link between Cyk3 and Rho1 that involves the TGc domain of Cyk3. Both *cyk3Δ* and *cyk3^TGcΔ^* mutants showed simultaneous formation of PS and SS, a synthetic growth defect with deletion of the Rho1 GAP gene *SAC7*, and a complete loss of the temporary inactivation of Rho1 during furrow ingression. Pull-down experiments showed that the C-terminal region of Cyk3 bound preferentially to inactive Rho1 and that this interaction was lost in the *cyk3^TGcΔ^* mutant, and BiFC assays reproduced these findings in vivo.

Transglutaminases from bacterial toxins and human cells have been shown to directly deamidate or transglutaminate Gln-63 of human RhoA ([@bib37]; [@bib83]; [@bib86]), causing a loss of GTPase activity and thus constitutive activity of the protein. Interestingly, the TGc domain in Cyk3 lacks a Cys (Pro in Cyk3) that is one of the three residues critical for transglutaminase activity ([@bib58]; [@bib75]) and so should be enzymatically inactive. Therefore, Cyk3 may function by binding to Rho1 without modifying or activating it. Because the switch II region of RhoA is necessary and sufficient for its recognition by the bacterial toxin transglutaminases CNF1 and DNT ([@bib50]; [@bib39]) and is also the central recognition site for Rho-GEFs ([@bib36]), the binding of Cyk3 to Rho1-GDP could interfere with its normal activation by Rho-GEFs ([Fig. 9 B](#fig9){ref-type="fig"}).

Because Rho1 appears to have an inhibitory effect on PS formation and thus furrow ingression, it is possible that the promotion of PS formation by overexpression of Cyk3 may be through an inhibition of Rho1. However, we consider this to be unlikely because the phenotype of *cyk3Δ* is more severe than *cyk3^TGcΔ^*, and unlike *cyk3^TGcΔ^*, mutations in the N-terminal region (*cyk3^W45A^* and *cyk3^P188,191A^*) did not show genetic interactions with *sac7Δ*. Both of these results suggest that the N-terminal and C-terminal regions of Cyk3 have genetically separable roles. Therefore, Cyk3 appears to be a bifunctional protein, with its N-terminal region involved in promoting PS formation through interactions with Inn1 and Hof1, and its C-terminal region involved in suppression of SS formation through interaction with Rho1.

It is presently unclear how Rho1 is reactivated for SS formation ([Fig. 9 C](#fig9){ref-type="fig"}). Although the BiFC signal between Cyk3 and Rho1 persisted after AMR disassembly, this signal may well be an artifact caused by the inherent irreversibility of binding of the BiFC probes that hinders its use for analysis of dissociation between two molecules ([@bib44]). Thus, it seems more likely that Cyk3 dissociates from Rho1 to allow its reactivation and that the dissociation is regulated by some mechanism such as phosphorylation.

A conserved role for transglutaminase-like domains in cytokinesis?
------------------------------------------------------------------

There appears to exist a subclass of eukaryotic transglutaminase-like proteins that lack one or more of the three residues required for catalytic activity ([@bib58]), and some of them have been implicated in cytokinesis. For example, a *Schizosaccharomyces pombe cyk3Δ* mutant shows reduced efficiency of PS formation and premature SS formation in certain mutant backgrounds ([@bib75]), suggesting that the *S. pombe* and *S. cerevisiae* proteins have similar roles despite the apparent differences in cell wall compositions and mechanisms of cytokinesis between these yeasts. Moreover, overexpression of *S. pombe* Cyk3 induces cell wall damage and morphology defects ([@bib75]), which could be a consequence of Rho1 inhibition. *Drosophila* hillarin is concentrated at the cleavage furrow during cell division, and in a septin mutant background, a mutation in hillarin causes increased polyploidy ([@bib41]). Similarly, *Caenorhabditis elegans* Ltd-1 is expressed during seam cell division and localizes in a pattern reminiscent of actin ([@bib93]). It will be interesting to determine whether these other transglutaminase-like proteins also function, at least in part, by regulating Rho proteins.

Materials and methods
=====================

Strains, plasmids, growth conditions, genetic methods, and reagents
-------------------------------------------------------------------

The yeast strains and plasmids used are listed in [Table 1](#tbl1){ref-type="table"} and [Table 2](#tbl2){ref-type="table"}. Standard culture media (including the buffered rich medium YM-P) and genetic techniques were used ([@bib52]; [@bib107]). The PCR method ([@bib54]) was used for gene deletion and tagging except where noted. 1 mg/ml 5-fluoroorotic acid (5-FOA; Research Products International) was added where noted. Cell cycle synchronization using *cdc15-2* or nocodazole (Toronto Research Chemicals) was performed essentially as described by [@bib29]. In brief, *cdc15-2* cells were cultured at 24°C in either YM-P medium or synthetic complete (SC) medium with appropriate supplements and carbon sources to early log phase (OD~600~ ≈ 0.2) and then arrested by gradually increasing the temperature to 37°C. After 3 h, the cells were released by rapidly cooling the medium to 24°C on ice. For nocodazole synchronization, cells were cultured in YPD medium at 24°C to early log phase, and nocodazole was added at 15 µg/ml. After 2 h, the cells were collected and washed by filtration and then resuspended in fresh medium. Aniline blue was obtained from EMD Millipore, and a 0.1% Ponceau S solution was obtained from Sigma-Aldrich.

###### 

Yeast strains used in this study

  Strain    Genotype                                                                                                   Source
  --------- ---------------------------------------------------------------------------------------------------------- ---------------------------------------------
  YEF473A   *MATa his3 leu2 lys2 trp1 ura3*                                                                            [@bib10]
  YEF473B   *MAT*α *his3 leu2 lys2 trp1 ura3*                                                                          [@bib10]
  KN143     As YEF473B except *LEU2:P~GAL1~-RHO1^Q68L^*                                                                This study[a](#tblfn1){ref-type="table-fn"}
  KO969     As YEF473A except *iqg1Δ::his3MX6*                                                                         This study
  KO1372    As RNY2242 except (YEp13-RHO1)                                                                             This study
  MWY636    As YEF473A except *cyk3^P188,191A^*                                                                        Our laboratory
  MWY1412   As YEF473A except *cyk3^W45A^*                                                                             Our laboratory
  RNY469    AsYEF473A except *myo1Δ::kanMX6* (pRS316GW-MYO1)                                                           This study
  RNY502    As YEF473A except *cyk3Δ::TRP1*                                                                            This study
  RNY875    As YEF473A except *rom2Δ::TRP1*                                                                            This study
  RNY879    As YEF473A except *tus1Δ::His3MX6*                                                                         This study
  RNY935    As YEF473A except *rom1Δ::His3MX6*                                                                         This study
  RNY1419   As YEF473A except *chs2Δ::kanMX6* (pJC328)                                                                 This study
  RNY1681   As YEF473A except *MYO1-GFP:kanMX6*                                                                        This study
  RNY2046   As YEF473B except *cdc15-2 MYO1-CFP:kanMX6*                                                                This study
  RNY2127   As YEF473A except *cyk3Δ::kanMX6 hof1Δ::TRP1* (pRS316GW-HOF1)                                              This study
  RNY2150   As YEF473A except *cyk3Δ::URA3-kanMX6*                                                                     This study
  RNY2242   As YEF473A except *iqg1Δ::His3MX6* (pRS316GW-IQG1)                                                         This study
  RNY2299   As YEF473A except *hof1Δ::kanMX6*                                                                          This study
  MOY22     As YEF473A except *HOF1-TAP:His3MX6*                                                                       This study
  MOY66     As YEF473B except *cyk3Δ::TRP1 hof1Δ::kanMX6* (pRS316GW-HOF1)                                              This study
  MOY68     As YEF473A except *cyk3Δ::TRP1 hof1Δ::kanMX6* (pRS316GW-HOF1)                                              This study
  MOY78     As MOY68 except (YEp13-cdc24\*)                                                                            This study
  MOY245    As MOY66 except (YEp13-RHO1)                                                                               This study
  MOY355    AS RNY2242 except (YEp13-RGD2)                                                                             This study
  MOY403    As YEF473B except *PXL1-GFP:His3MX6*                                                                       This study
  MOY404    As YEF473B except *pxl1Δ::His3MX6*                                                                         This study
  MOY405    As YEF473B except *sac7Δ::His3MX6*                                                                         This study
  MOY407    As YEF473B except *lrg1Δ::His3MX6*                                                                         This study
  MOY428    As YEF473B except *myo1Δ::kanMX6 pxl1Δ::His3MX6* (pRS316GW-MYO1)                                           This study
  MOY429    As YEF473A except *cyk3Δ::TRP1 pxl1Δ::His3MX6*                                                             This study
  MOY430    As YEF473B except *cyk3Δ::TRP1 hof1Δ::kanMX6 pxl1Δ::His3MX6* (pRS316GW-HOF1)                               This study
  MOY433    As YEF473A except *cyk3Δ::TRP1 hof1Δ::kanMX6 lrg1Δ::His3MX6* (pRS316GW-HOF1)                               This study
  MOY438    As YEF473A except *cyk3Δ::TRP1 hof1Δ::kanMX6 sac7Δ::His3MX6* (pRS316GW-HOF1)                               This study
  MOY440    As YEF473B except *cyk3Δ::TRP1 sac7Δ::His3MX6*                                                             This study
  MOY445    As YEF473A except *hof1Δ::kanMX6 pxl1Δ::His3MX6*                                                           This study
  MOY522    As YEF473A except *rho1Δ::his3MX6 URA3:3HA-RHO1*                                                           This study[b](#tblfn3){ref-type="table-fn"}
  MOY526    As YEF473A except *MYO1-CFP:kanMX6 PXL1-GFP:His3MX6*                                                       This study
  MOY542    As YEF473A except *cdc15-2 MYO1-GFP:kanMX6* (YCp-P~GAL~-RHO1^T24N^)                                        This study
  MOY543    As YEF473B except *cdc15-2 CYK3-GFP:kanMX6*                                                                This study
  MOY552    As YEF473B except *rho1Δ::his3MX6 URA3:3HA-RHO1 cdc15-2 cyk3Δ::kanMX6*                                     This study
  MOY553    As YEF473B except *rho1Δ::his3MX6 URA3:3HA-RHO1 cdc15-2*                                                   This study
  MOY585    As YEF473A except *cyk3Δ::TRP1*                                                                            This study
  MOY681    As MOY68 except (pGP564-RHO2)                                                                              This study
  MOY682    As MOY68 except (YEp13-RGD2)                                                                               This study
  MOY691    As YEF473B except *cyk3Δ::TRP1 LEU2:P~GAL1~-RHO1^Q68L^*                                                    This study
  MOY720    As YEF473A except *cdc15-2 MYO1-GFP:kanMX6*                                                                This study
  MOY721    As YEF473B except *cdc15-2 MYO1-GFP:kanMX6 cyk3Δ::kanMX6*                                                  This study
  MOY801    As YEF473A except (YCp-P~GAL~-3HA-RHO1)                                                                    This study
  MOY803    As YEF473A except (YCp-P~GAL~-3HA-RHO1^Q68L^)                                                              This study
  MOY824    As YEF473A except (YCp-P~GAL~-3HA-RHO1^T24N^)                                                              This study
  MOY882    As YEF473A except *cyk3^TGcΔ^*                                                                             This study[c](#tblfn5){ref-type="table-fn"}
  MOY967    As YEF473A except *sac7Δ::His3MX6 cyk3^TGcΔ^*                                                              This study
  MOY973    As YEF473A except *cyk3^TGcΔ^ rho1Δ::His3MX6 URA3:3HA-RHO1 cdc15-2*                                        This study
  MOY980    As YEF473A except *sac7Δ::His3MX6 cyk3^P188,191A^*                                                         This study
  MOY982    As YEF473A except *sac7Δ::His3MX6 cyk3^W45A^*                                                              This study
  MOY1247   As YEF473B except *rho1Δ::His3MX6 MYO1-CFP:kanMX6* (pRS315-VC-GGS~2~-RHO1)                                 This study
  MOY1269   As YEF473A except *TUS1-VN173:His3MX6 rho1Δ::His3MX6* (pRS315-VC-GGS~2~-RHO1)                              This study
  MOY1275   As YEF473A except *SAC7-VN173:His3MX6 rho1Δ::His3MX6* (pRS315-VC-GGS~2~-RHO1)                              This study
  MOY1293   As YEF473A except *ROM2-VN173:TRP1 rho1Δ::His3MX6* \[pRS315-VC-GGS~2~-RHO1\]                               This study
  MOY1294   As YEF473A except *LRG1-VN173:TRP1 rho1Δ::His3MX6* (pRS315-VC-GGS~2~-RHO1)                                 This study
  MOY1303   *MAT*α (*ade2 or ADE2) his3 lys2 trp1 ura3 Δfks1::HIS3 ade3::FKS1-GFP::LEU2 MYO1-CFP:kanMX6 Δfks2::LYS2*   This study[d](#tblfn7){ref-type="table-fn"}
  MOY1321   As YEF473A except *CYK3-VN155^I152L^:TRP1*                                                                 This study
  MOY1325   As YEF473B except *CYK3-VN155*^I152L:TRP1\ rho1Δ*::His3MX6*\ (pRS315-VC-GGS^~2~^-RHO1)^                    This study
  MOY1349   As YEF473B except *CYK3-VN155^I152L^:TRP1 rho1Δ::His3MX6 MYO1-CFP:kanMX6* (pRS315-VC-GGS~2~-RHO1)          This study
  MOY1384   As YEF473A except *CYK3^TGcΔ-VN155I152L^:TRP1 rho1Δ::His3MX6* (pRS315-VC-GGS~2~-RHO1)                      This study

Except where noted, strains were constructed using conventional genetic crosses, the PCR method ([@bib7]; [@bib54]) for deletion and tagging of chromosomal genes, and/or plasmid transformations ([Table 2](#tbl2){ref-type="table"}). The *cdc15-2* marker was introduced as described by [@bib69]. In addition to the PCR tagging plasmids described by [@bib54], similar plasmids contained CFP sequences (unpublished data), TAP tag sequences (provided by P. Walter, University of California, San Francisco, San Francisco, CA), *URA3-kanMX6* (unpublished data), *VN173* ([@bib87]), or *VN155^I153L^* ([Table 2](#tbl2){ref-type="table"}).

Constructed by transforming EcoRV-digested YIp128-P~GAL1~RHO1^Q68L^ into YEF473B.

Constructed by transforming NcoI-digested pRS306-3HA-RHO1 into a YEF473-background *rho1Δ::His3MX6/RHO1* heterozygote and selecting Ura ^+^ His^+^ segregants.

Constructed by digesting pRS315-cyk3^TGcΔ^ with SphI (at −384 relative to the *CYK3* start codon) and SacII (at 2,935, 464 bp downstream of the stop codon), transforming into strain RNY2150, and selecting Ura^−^ colonies on an SC + 5-FOA plate. Correct integration was confirmed by showing kanamycin sensitivity and PCR amplifying genomic DNA using appropriate primers.

Constructed by crossing YOC2439 (*MATa ade2 his3 lys2 trp1 ura3 Δfks1::HIS3 Δfks2::LYS2 ade3::FKS1-GFP::LEU2*; a gift from Y. Ohya, University of Tokyo, Tokyo, Japan) and RNY2046.

###### 

Plasmids used in this study

  Plasmid                                                                               Description[a](#tblfn8){ref-type="table-fn"}                                  Reference or source
  ------------------------------------------------------------------------------------- ----------------------------------------------------------------------------- ----------------------------------------------
  pGEX-2T                                                                               For expression of GST in *E. coli*                                            GE Healthcare
  pGEX-RBD (PKC1)                                                                       For expression of GST-RBD (Pkc1) in *E. coli*                                 [@bib102]; [@bib45]
  pGEX2T-CYK3                                                                           For expression of GST-Cyk3 in *E. coli*                                       See Supplemental material
  pGEX2T-CYK3^480--885^                                                                 For expression of GST-Cyk3^480-885^ in *E. coli*                              See Supplemental material
  YEp13[b](#tblfn9){ref-type="table-fn"}                                                2µ and *LEU2*                                                                 [@bib79]
  pJC328                                                                                *CEN*, *URA3*, and *CHS2*-*MYC*                                               [@bib18]
  YCp111-CDC3-CFP                                                                       *CEN*, *LEU2*, and *CDC3*-*CFP*                                               [@bib69]
  pRS316GW-IQG1                                                                         *CEN*, *URA3*, and *IQG1*                                                     [@bib69]
  pRS316GW-HOF1                                                                         *CEN*, *URA3*, and *HOF1*                                                     Unpublished data
  pRS425GW-CYK3[b](#tblfn9){ref-type="table-fn"}                                        2µ, *LEU2*, and *CYK3*                                                        Unpublished data
  pRS316GW-MYO1                                                                         *CEN*, *URA3*, and *MYO1*                                                     Unpublished data
  YEp13-RHO1[b](#tblfn9){ref-type="table-fn"}                                           2µ, *LEU2*, and *RHO1*                                                        This study[c](#tblfn10){ref-type="table-fn"}
  pGP564-RHO2[b](#tblfn9){ref-type="table-fn"}                                          2µ, *LEU2*, *RHO2*, and neighboring genes[d](#tblfn11){ref-type="table-fn"}   This study[e](#tblfn12){ref-type="table-fn"}
  YEp13-RGD2[b](#tblfn9){ref-type="table-fn"}                                           2µ, *LEU2*, and *RGD2*                                                        This study[c](#tblfn10){ref-type="table-fn"}
  YEp13-cdc24\*[b](#tblfn9){ref-type="table-fn"}^,^[f](#tblfn13){ref-type="table-fn"}   2µ, *LEU2*, and *cdc24\**                                                     This study[c](#tblfn10){ref-type="table-fn"}
  YEp13-CDC24[b](#tblfn9){ref-type="table-fn"}^,^[f](#tblfn13){ref-type="table-fn"}     2µ, *LEU2*, and *CDC24*                                                       See Supplemental material
  pSD1[b](#tblfn9){ref-type="table-fn"}                                                 2µ, *LEU2*, and *MSS4*                                                        M.N. Hall[g](#tblfn14){ref-type="table-fn"}
  YEp13-KDX1[b](#tblfn9){ref-type="table-fn"}                                           2µ, *LEU2*, and *KDX1*                                                        This study[c](#tblfn10){ref-type="table-fn"}
  pGP564-PSP1[b](#tblfn9){ref-type="table-fn"}                                          2µ, *LEU2*, *PSP1*, and neighboring genes[d](#tblfn11){ref-type="table-fn"}   This study[e](#tblfn12){ref-type="table-fn"}
  YEp13-NAB6[b](#tblfn9){ref-type="table-fn"}                                           2µ, *LEU2*, *NAB6*, and neighboring genes[d](#tblfn11){ref-type="table-fn"}   This study[c](#tblfn10){ref-type="table-fn"}
  YEp13-PAP1[b](#tblfn9){ref-type="table-fn"}                                           2µ, *LEU2*, and *PAP1*                                                        This study[c](#tblfn10){ref-type="table-fn"}
  pRS425GW-TUS1[b](#tblfn9){ref-type="table-fn"}                                        2µ, *LEU2*, and *TUS1*                                                        See Supplemental material
  pRS425GW-ROM1[b](#tblfn9){ref-type="table-fn"}                                        2µ, *LEU2*, and *ROM1*                                                        See Supplemental material
  pRS425GW-ROM2[b](#tblfn9){ref-type="table-fn"}                                        2µ, *LEU2*, and *ROM2*                                                        See Supplemental material
  pRS425GW-RGD1[b](#tblfn9){ref-type="table-fn"}                                        2µ, *LEU2*, and *RGD1*                                                        See Supplemental material
  YEp181-RGA1[b](#tblfn9){ref-type="table-fn"}                                          2µ, *LEU2*, and *RGA1*                                                        [@bib15]
  YEp181-RGA2[b](#tblfn9){ref-type="table-fn"}                                          2µ, *LEU2*, and *RGA2*                                                        See Supplemental material
  YEp181-BEM2[b](#tblfn9){ref-type="table-fn"}                                          2µ, *LEU2*, and *BEM2*                                                        Unpublished data
  YEp13-BEM3[b](#tblfn9){ref-type="table-fn"}                                           2µ, *LEU2*, and *BEM3*                                                        [@bib10]
  pRS425GW-SAC7[b](#tblfn9){ref-type="table-fn"}                                        2µ, *LEU2*, and *SAC7*                                                        See Supplemental material
  pRS425GW-LRG1[b](#tblfn9){ref-type="table-fn"}                                        2µ, *LEU2*, and *LRG1*                                                        See Supplemental material
  pGP564-BAG7[b](#tblfn9){ref-type="table-fn"}                                          2µ, *LEU2*, *BAG7*, and neighboring genes[d](#tblfn11){ref-type="table-fn"}   This study[e](#tblfn12){ref-type="table-fn"}
  YEp13-cdc24ΔPB1[f](#tblfn13){ref-type="table-fn"}                                     2µ, *LEU2*, and *cdc24ΔPB1*                                                   See Supplemental material
  YEp13-cdc24\*-DH8[f](#tblfn13){ref-type="table-fn"}                                   2µ, *LEU2*, and *cdc24\** with N452G and E453G mutations                      See Supplemental material
  pRS425-CDC24-GFP[f](#tblfn13){ref-type="table-fn"}                                    2µ, *LEU2*, and *CDC24-GFP*                                                   See Supplemental material
  YEp13-cdc24\*-GFP[f](#tblfn13){ref-type="table-fn"}                                   2µ, *LEU2*, and *cdc24ΔPB1-GFP-tetA*                                          See Supplemental material
  pRS425-cdc24ΔPB1-GFP[f](#tblfn13){ref-type="table-fn"}                                2µ, *LEU2*, and *cdc24ΔPB1-GFP*                                               See Supplemental material
  YCp-P~GAL~-RHO1^T24N^                                                                 *CEN*, *LEU2*, and *P~GAL~-RHO1^T24N^*                                        See Supplemental material
  YIp128-P~GAL~-RHO1^Q68L^                                                              Integrative, *LEU2*, and *P~GAL~-RHO1^Q68L^*                                  See Supplemental material
  pRS306-3HA-RHO1                                                                       Integrative, *URA3*, and *3HA-RHO1*                                           See Supplemental material
  YCp-P~GAL~-3HA-RHO1                                                                   *CEN*, *LEU2*, and *P~GAL~-3HA-RHO1*                                          See Supplemental material
  YCp-P~GAL~-3HA-RHO1^Q68L^                                                             *CEN*, *LEU2*, and *P~GAL~-3HA-RHO1^Q68L^*                                    See Supplemental material
  YCp-P~GAL~-3HA-RHO1^T24N^                                                             *CEN*, *LEU2*, and *P~GAL~-3HA-RHO1^T24N^*                                    See Supplemental material
  pFA6a-VN173:TRP1                                                                      PCR template for chromosomal tagging with VN173                               [@bib87]
  pFA6a-VN173:His3MX6                                                                   PCR template for chromosomal tagging with VN173                               [@bib87]
  pFA6a-VC155-TRP1                                                                      PCR template for chromosomal tagging with VC155                               [@bib87]
  pFA6a-VN155^I153L^-TRP1                                                               PCR template for chromosomal tagging with VN155^I153L^                        See Supplemental material
  pRS315-VC-GGS~2~-RHO1                                                                 *CEN*, *LEU2*, and *VC155-GGSGGS-RHO1*                                        See Supplemental material
  pRS315-CYK3^TGcΔ^[h](#tblfn15){ref-type="table-fn"}                                   *CEN*, *LEU2*, and *CYK3* lacking bp 1,556--1,739                             See Supplemental material

*CEN* indicates a low-copy number plasmid; 2µ indicates a high-copy number plasmid; integrative indicates a plasmid without a yeast replication origin.

Used in [Fig. 2 A](#fig2){ref-type="fig"} and/or Fig. S1.

Isolated in the suppressor screen using the YEp13-based library (see Materials and methods) or by subcloning a single-gene fragment from the originally isolated plasmid back into YEp13.

The actual plasmids used in the experiments shown in this paper are listed. The genes responsible for suppression were confirmed by further truncation.

Isolated from a genomic tiling library (Thermo Fisher Scientific).

Used in Fig. S3.

University of Basel, Basel, Switzerland.

Used for construction of strain MOY882.

Plasmid constructions
---------------------

To construct pGEX2T-CYK3 and pGEX2T-CYK3^480--885^, the appropriate regions were PCR amplified from yeast genomic DNA with BamHI and HindIII sequences on the 5′ and 3′ ends, respectively, and inserted between the corresponding sites in pGEX-2T. YEp13-CDC24 was constructed by PCR amplifying a DNA fragment containing nucleotides 2,296--2,859 relative to the start site of *CDC24* and 1--40 relative to the SphI of YEp13 (incorporated in the primer) using pRS315-CDC24 (provided by E. Bi, University of Pennsylvania, Philadelphia, PA) as a template. This fragment was cloned by gap repair into SphI-digested YEp13-cdc24\* ([Table 2](#tbl2){ref-type="table"}) by cotransforming into YEF473A.

pRS315GW-HOF1, pRS315GW-MYO1, pRS425GW-CYK3, pRS425GW-TUS1, pRS425GW-ROM1, pRS425GW-ROM2, pRS425GW-RGD1, pRS425GW-SAC7, and pRS425GW-LRG1 were constructed as follows. Genomic DNA fragments containing each gene were amplified by PCR (positions relative to the start sites: *HOF1*, −1,000 to 2,510; *MYO1*, −782 to 6,150; *CYK3*, −900 to 3,248; *TUS1*, −500 to 4,424; *ROM1*, −1,000 to 3,968; *ROM2*, −500 to 4,571; *RGD1*, −1,000 to 2,501; *SAC7*, −1,000 to 2,465; and *LRG1*, −1,000 to 3,554), cloned into the pCR8/GW/TOPO vector (Invitrogen), and transferred into pRS315-attR or pRS425-attR (this study) by Gateway recombination (Invitrogen). YEp181-RGA2 was constructed by ligating a SacI--KpnI fragment from pDLB1981 ([@bib33]) into the corresponding sites of YEplac181 ([@bib32]).

YEp13-cdc24ΔPB1 was constructed by using a mutagenesis kit (QuikChange; Agilent Technologies) to introduce a stop codon into YEp13-cdc24\* immediately before the BamHI site at the junction between the *CDC24* and *tetA* coding sequences. YEp13-cdc24\*-DH8 was constructed in two steps. First, a fragment containing nucleotides 764--1,659 relative to the start site of *CDC24* and two mutations (N452G and E453G) within the DH (Dbl homology) domain was PCR amplified using plasmid pRS414-3×mycCdc24-DH8 (provided by R. Arkowitz, Université de Nice, Nice, France) as a template. The PCR product was then cloned by gap repair into BbvCI-cut YEp13-cdc24\*. To construct pRS425-CDC24-GFP, an XhoI fragment from pRS315-CDC24-GFP (provided by E. Bi) was integrated by gap repair into NotI-digested pRS425 ([@bib17]). YEp13-cdc24\*-GFP was constructed in three steps. First, a DNA fragment containing base pairs 2,261--2,281 of *CDC24*, the GFP sequence, and base pairs 1--40 relative to the BamHI site of YEp13 (incorporated in the primer) was PCR amplified using pRS315-CDC24-GFP as a template. Second, pRS315-CDC24-GFP was digested by NheI and BglII to generate a DNA fragment containing base pairs −146 to −1 relative to the BamHI site of YEp13 and the *CDC24* gene. Finally, these two fragments were integrated into BamHI-digested YEp13 by gap repair. YEp13-cdc24ΔPB1-GFP was constructed in the same way except that a primer generating a stop codon between the GFP sequence and the BamHI site was used in the PCR step.

YCp-P~GAL~-RHO1^T24N^ was constructed as follows. First, site-directed mutagenesis was performed in pRS316-RHO1 (this study) using the QuikChange kit (primer 5′-CTGTGGTAAGAACTGTTTATTAATC-3′ and its complement). The resulting pRS316-RHO1^T24N^ did not yield any yeast transformants, presumably as a result of dominant lethality of this allele. Next, the *RHO1^T24N^* ORF was PCR amplified with DNA fragments homologous to base pairs −40 to −1 and 1--40 relative to the SalI site of YCpIF2 ([@bib27]) at the 5′ and 3′ ends, respectively. Finally, this PCR product was integrated into SalI-digested YCpIF2 by gap repair. YIp128-P~GAL~-RHO1^Q68L^ was constructed as follows. First, the NdeI--SacI fragment containing *RHO1^Q68L^* from pRS304-P~cdc42~-12myc-RHO1^Q68L^ was inserted into the corresponding sites of pRS304-P~GAL1~ (both plasmids provided by D. Lew, Duke University, Durham, NC). From the resulting plasmid, a DNA fragment containing P~GAL~-RHO1^Q68L^ was released by digestion with EcoRI and SacI and ligated into the corresponding sites of YIp128 ([@bib32]).

To construct pRS306-3HA-RHO1, plasmid pRS316-RHO1 was digested at the NotI site in the vector, blunt ended, and self-ligated to eliminate the site. A new NotI site was then introduced immediately downstream of the *RHO1* start codon by site-directed mutagenesis using the QuikChange kit. A DNA fragment encoding 3HA with NotI site ends was then PCR amplified using YEpHA-BUD8F ([@bib81]) as a template and inserted at the new NotI site. Finally, the insert of this plasmid was transferred into pRS306 using the HindIII and SacI sites in both plasmids. YCp-P~GAL~-3HA-RHO1, YCp-P~GAL~-3HA-RHO1^T24N^, and YCp-P~GAL~-3HA-RHO1^Q68L^ were constructed using the same approach as for YCp-P~GAL~-RHO1^T24N^ (see preceding paragraph), using pRS316-RHO1, pRS316-RHO1^T24N^, and pRS304-P~cdc42~-12myc-RHO1^Q68L^ (provided by D. Lew) as PCR templates. The PCR products were integrated into SalI--PstI-digested YCpIF2-3HA-BUD8 (this study).

Plasmid pFA6a-VN155^I153L^-TRP1 was constructed by PCR amplifying a fragment encoding aa 1--155 of Venus using pFA6a-VN173-TRP1 ([@bib87]) as a template and incorporating an I to L mutation at aa 153; the PCR used an F2 primer ([@bib54]) with a BamHI site upstream of the coding sequence and a reverse primer (5′-ATTTAGAAGT[GGCGCGCC]{.ul}CTAGGCGGTGAGATAGACGTTGTGGCT-3′) that included an AscI site (underlined). The PCR product was digested with BamHI and AscI and then ligated into the corresponding sites of pFA6a-VC155-TRP1. Plasmid pRS315-VC-GGS~2~-RHO1 was constructed by PCR amplifying a sequence encoding the C-terminal portion of Venus using pFA6a-VC155-TRP1 as a template and primers (5′-GAAAGATGT[GCGGCCGC]{.ul}CGTCCGGCGTGCAAAATCCCG-3′ and 5′-GG[GGATCC]{.ul}CTTGTACAGCTCGTCCATGCCGAGA-3′) that included NotI and BamHI sites (underlined). The PCR product was digested with NotI and BamHI and then ligated into the corresponding sites of pRS315-GFP-GGS~2~-RHO1 (this study).

To construct plasmid pRS315-CYK3^TGcΔ^, two DNA fragments containing genomic regions around the *CYK3* ORF were PCR amplified using plasmid pRS315-CYK3 (this study) as a template and primers 5′-ATTAACCCTCACTAAAGGGA-3′ and 5′-CATTTCCTAAGTATAGTATTTTCTCTAAATTTTGG-3′ (fragment 1) and 5′-AATACTATACTTAGGAAATGTAACCAACCCAATTC-3′ and 5′-TAATACGACTCACTATAGGG-3′ (fragment 2). Fragment 1 contained the promoter and base pairs 1--1,555 of the *CYK3* ORF, and fragment 2 contained base pairs from 1,740 of the ORF through the stop codon and terminator. These two fragments have 20 bp of homologous sequence at their 1,555 and 1,740 ends and were integrated into ApaI--SacI-digested pRS315 ([@bib85]) by gap repair.

Identification of multicopy suppressors for *cyk3Δ hof1Δ*
---------------------------------------------------------

A *cyk3Δ hof1Δ* strain carrying a low-copy, *URA3*-marked *HOF1* plasmid (MOY66) was transformed with a *LEU2*-marked high-copy (2µ) library in plasmid YEp13 ([@bib20]), grown on a SC-Ura-Leu plate to form colonies, and replica plated onto SC-Leu + 5-FOA to select for ability to lose the *HOF1* plasmid. From 35 transformants identified initially, plasmid recovery and retransformation yielded 22 plasmids that reproducibly rescued strain MOY66. Subcloning and/or deletion analyses identified the suppressor genes in 16 of these plasmids as (numbers of isolates in parentheses) *CYK3* (3), *HOF1* (2), *RHO1* (2), *KDX1* (2), *RGD2* (1), *cdc24*\* (1), *PAP1* (2), *NAB6* (2), and the 5-FOA resistance gene *YJL055W* (1; [@bib43]). The remaining six plasmids contained distinct genome fragments in which the suppressor genes have not been determined. A parallel screen used a yeast genomic tiling library (Thermo Fisher Scientific) that was pooled from 384-well plates to five sublibraries and transformed separately; it yielded 26 plasmids that contained *HOF1* (five plasmids), *RHO1* (five plasmids), *RHO2* (two plasmids), *MSS4* (three plasmids), and *RGD2* (11 plasmids), plus other plasmids that were isolated once each and not analyzed further.

Light microscopy and EM
-----------------------

Differential interference contrast and fluorescence microscopy were performed using a microscope (Eclipse 600-FN; Nikon), an Apochromat 100×/1.40 NA oil immersion objective, a cooled charge-coupled device camera (ORCA-2; Hamamatsu Photonics), and MetaMorph version 7.0 software (Molecular Devices). Most time-lapse microscopy was performed using the same equipment, by sandwiching cells suspended in SC medium between a coverslip and a slide and sealing with VALAP, as described previously ([@bib69]). In one case ([Fig. 5](#fig5){ref-type="fig"}), the cells were spotted on a thin layer of YPD medium + 1% low-melting agarose (SeaPlaque; FMC Corporation), which was then placed on a coverslip. EM was performed essentially as described by [@bib75]: cells were collected by filtration, fixed with glutaraldehyde and potassium permanganate, embedded in LR white resin (Fluka; Sigma-Aldrich), and stained with uranyl acetate and lead citrate. Images were obtained using a microscope (JEM-1230; JEOL) equipped with a cooled charge-coupled device camera (967 or Orius SC1000A; Gatan). Images were postprocessed using the MetaMorph, Photoshop (Adobe), and/or ImageJ (National Institutes of Health) software.

Biochemistry
------------

Expression and purification of GST-tagged proteins from *Escherichia coli* BL21 (DE3 and pLysS) were performed as described by [@bib28]. In brief, *E. coli* strains transformed with the expression vectors were cultured in LB medium at 37°C to OD~600~ ≈ 0.3, and IPTG was added at 0.1 mM. The cells were collected by centrifugation after 3 h of incubation at 37°C, resuspended in STE (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 1 mM EDTA) + 0.1 mg/ml lysozyme, and incubated for 15 min on ice. The cells were lysed by addition of 1.5% (final concentration) sarkosyl and brief sonication on ice, and the lysate was cleared by centrifugation at 12,000 *g* for 5 min at 4°C. Supernatants were supplemented with 2% (final concentration) Triton X-100, incubated with glutathione--Sepharose beads for 1 h at 4°C and then washed three times with Rho pull-down (RPD) or RIPA buffer (see below) depending on the downstream application. The beads were then resuspended in the same buffer supplemented with 10% glycerol and stored at −80°C. The pull-down assays using the RBD from Pkc1 was performed as described by [@bib45] with modifications. In brief, protein extracts were prepared from frozen yeast cells using glass beads in RPD buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 12 mM MgCl~2~, 1 mM DTT, and 1% NP-40) supplemented with a complete protease inhibitor cocktail (Roche), and centrifuged at 12,000 *g* for 10 min. 3 mg of each cleared extract was incubated with 10 µl GST-RBD beads for 1 h at 4°C, washed three times with RPD buffer, and eluted by boiling in SDS sample buffer for 3 min. Samples were analyzed by SDS-PAGE (14%) and Western blotting using a peroxidase-conjugated mouse anti-HA antibody (3F10; Roche). 15 µg of the cleared extract was loaded in the input lanes. The pull-down assay using GST-Cyk3 and GST-Cyk3^(480--885)^ was performed similarly but using RIPA buffer (6 mM Na~2~HPO~4~, 4 mM NaH~2~PO~4~, 150 mM NaCl, 2 mM EDTA, 1 mM DTT, 50 mM NaF, 0.1 mM NA~3~VO~4~, 1% Triton X-100, 1% sodium deoxycholate, and 0.1% SDS) for protein extraction and incubation with the beads. Samples were analyzed by SDS-PAGE (14% for 3HA-Rho1 and 10% for Hof1--tandem affinity purification (TAP) and Western blotting using the anti-HA antibody or (for Hof1-TAP) peroxidase antiperoxidase soluble complex (Sigma-Aldrich).

Online supplemental material
----------------------------

Fig. S1 shows an expanded version of the data shown in [Fig. 2 A](#fig2){ref-type="fig"}, and also includes the *iqg1Δ* suppression results and the suppression by some GEFs and GAPs. Fig. S2 shows EM images of *cyk3Δ hof1Δ* and *iqg1Δ* cells expressing some of the suppressors. Fig. S3 shows a detailed characterization of *cdc24\**, which lead to the conclusion that it inhibits the Cdc42 pathway. Fig. S4 shows data implicating Pxl1 in regulation of SS formation. Fig. S5 shows supporting evidence of cytokinesis defects caused by ectopically activated Rho1. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201302001/DC1>.
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